WCLC 2025 - Posters & ePosters-PT2.14.04 Efficacy and Safety of Adebrelimab Plus Chemotherapy as Neoadjuvant Treatment for Unresectable Locally Advanced Thymic Carcinoma

PT2.14.04 Efficacy and Safety of Adebrelimab Plus Chemotherapy as Neoadjuvant Treatment for Unresectable Locally Advanced Thymic Carcinoma

Back to course

Pdf Summary

This study assessed the efficacy and safety of neoadjuvant adebrelimab plus chemotherapy (nab-paclitaxel and carboplatin) in 9 treatment-naïve patients with unresectable locally advanced thymic squamous cell carcinoma (T3/T4NxM0). Patients (median age 51, 55.6% male) received three 3-week cycles of therapy before surgery and adjuvant radiotherapy/chemotherapy or definitive chemoradiotherapy. Staging included IIIA (33.3%), IIIB (33.3%), and IVB (33.3%) cases; all had ECOG performance status 1.<br /><br />At data cutoff (March 3, 2025), the objective response rate (ORR) was 44.4% (4/9), with the remaining 55.6% having stable disease, yielding a disease control rate (DCR) of 100%. Seven patients (77.8%) proceeded to surgery, all achieving complete (R0) resection at a median 37 days post-neoadjuvant therapy without surgical delays or deaths. Pathological evaluation showed a complete response (pCR) rate of 14.3% and major pathological response (MPR, ≤10% viable tumor cells) rate of 42.9%. Survival data (PFS, OS) were not mature.<br /><br />Safety was acceptable: all patients experienced adverse events (AEs), with grade 3-4 events in 77.8%, primarily neutropenia (55.6%), leukopenia (11.1%), and rash (11.1%). Immune-related AEs from adebrelimab were mostly grade 1-2 (55.6%), including rash and infusion reactions; one grade 3 rash occurred. No surgical complications related to treatment were observed.<br /><br />Conclusions highlight that neoadjuvant adebrelimab plus chemotherapy shows promising efficacy and manageable safety in unresectable locally advanced thymic carcinoma, supporting further study in an ongoing trial stage II. This regimen may improve outcomes where surgery alone or standard multimodal treatment is insufficient, addressing an unmet need in this rare malignancy.

Asset Subtitle

Ning Xu

Meta Tag

Speaker Ning Xu

Topic Mesothelioma, Thymoma, and Other Thoracic Tumors

Keywords

neoadjuvant adebrelimab

chemotherapy

nab-paclitaxel

carboplatin

thymic squamous cell carcinoma

unresectable locally advanced thymic carcinoma

objective response rate

complete resection

pathological response

treatment safety